Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma?

References

• 1  Mathers CC, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med.3(11),e442 (2006).
  MedlineGoogle Scholar
• 2  Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N. Engl. J. Med.345(26),1890–1900 (2001).
  Medline CASGoogle Scholar
• 3  Langer CC. Exploring biomarkers in head and neck cancer. Cancer118(16),3882–3892 (2012).
  Medline CASGoogle Scholar
• 4  Calli C, Calli A, Pinar E, Oncel S, Tatar B. Prognostic significance of p63, p53 and ki67 expression in laryngeal basaloid squamous cell carcinomas. B-ENT7(1),37–42 (2011).
  Medline CASGoogle Scholar
• 5  Ikeda H, Lethé B, Lehmann F et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity6(2),199–208 (1997).
  Medline CASGoogle Scholar
• 6  Tanaka N, Wang YH, Shiseki M, Takanashi M, Motoji T. Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells. Leuk. Res.35(9),1219–1225 (2011).
  Medline CASGoogle Scholar
• 7  Epping MT, Wang L, Edel MJ, Carlée L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell122(6),835–847 (2005).
  Medline CASGoogle Scholar
• 8  Epping MM, Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res.66(22),10639–10642 (2006).
  Medline CASGoogle Scholar
• 9  Schantz SS. Chemoprevention strategies: the relevance of premalignant and malignant lesions of the upper aerodigestive tract. J. Cell. Biochem. Suppl.17F,18–26 (1993).
  Medline CASGoogle Scholar
• 10  Lotan R, Xu XC, Lippman SM et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N. Engl. J. Med.332(21),1405–1410 (1995).
  Medline CASGoogle Scholar
• 11  Feng L, Wang Z. Clinical trials in chemoprevention of head and neck cancers. Rev. Recent Clin. Trials7(3),249–254 (2012).
  MedlineGoogle Scholar
• 12  Siddikuzzaman Guruvayoorappan C, Berlin Grace VM. All trans retinoic acid and cancer. Immunopharmacol. Immunotoxicol.33(2),241–249 (2011).
  MedlineGoogle Scholar
• 13  Li RJ, Ying X, Zhang Y et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J. Control. Release149(3),281–291 (2011).
  Medline CASGoogle Scholar
• 14  Gudas LL, Wagner JA. Retinoids regulate stem cell differentiation. J. Cell Physiol.226(2),322–330 (2011).
  Medline CASGoogle Scholar
• 15  Szczepanski MJ, DeLeo AB, Luczak M et al. PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions. Oral Oncol.49(2),144–151 (2013).
  Medline CASGoogle Scholar
• 16  Steele TO, Meyers A. Early detection of premalignant lesions and oral cancer. Otolaryngol. Clin. North Am.44(1),221–229, vii (2011).
  MedlineGoogle Scholar
• 17  Rhee JJ, Khuri FF, Shin DM. Advances in chemoprevention of head and neck cancer. Oncologist9(3),302–311 (2004).
  Medline CASGoogle Scholar
• 18  Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett.40(1),93–101 (1988).
  Medline CASGoogle Scholar
• 19  Brown G, Hughes P. Retinoid differentiation therapy for common types of acute myeloid leukemia. Leuk. Res. Treatment2012,939021 (2012).
  Google Scholar
• 20  Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J. Natl. Cancer Inst.86(2),140–141 (1994).
  Medline CASGoogle Scholar
• 21  Bioley G, Guillaume P, Luescher I et al. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157–165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing tumors. J. Immunother.32(2),161–168 (2009).
  Medline CASGoogle Scholar
• 22  Amir AL, van der Steen DM, van Loenen MM et al. PRAME-specific allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. Clin. Cancer Res.17(17),5615–5625 (2011).
  Medline CASGoogle Scholar
• 23  Visus C, Wang Y, Lozano-Leon A et al. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. Clin Cancer Res.17(19),6174–6184 (2011).
  Medline CASGoogle Scholar